Home > Health Care Professionals > Research > Pediatric Therapeutics
Research Pediatric Therapeutics
Research Pediatric Therapeutics

Our Innovations in Pediatric Therapeutics research pillar conducted more than 20 new early-phase clinical investigation in recent years — in areas which comprise pediatric cancer, diabetes and infectious diseases. Children's Mercy is proud to have the largest and most productive pediatric clinical pharmacology program in North America. 

Pediatric Therapeutic Research Highlights

Detection of Foreign Bodies

The Center for Prospective Clinical Trials in Pediatric Surgery, directed by Shawn D. St. Peter, MD, Professor of Surgery at the University of Missouri-Kansas City School of Medicine, has recently published results from a study which describes the predictors of foreign body aspiration in infants and children. Dr. St. Peter and his colleagues demonstrated that patients with a suspected foreign body aspiration should undergo diagnostic bronchoscopy given that traditional chest X-rays may not reveal the presence or position of the foreign body. 
Read more »

Treating Juvenile Arthritis

Mara Becker, MD, MSCE, Director of the Division of Pediatric Rheumatology, in conjunction with collaborators from the Division of Pediatric Pharmacology and Therapeutic Innovation, have described for the first time how variation in the different forms of folic acid within the cells of patients with Juvenile Idiopathic Arthritis are associated with the response to treatment with methotrexate, an old drug capable of modifying disease expression in JIA. 
Read more »

Programming Genes to Destroy Cancer Cells

Douglas Myers, MD, from the Division of Hematology/Oncology, with support from the Midwest Cancer Alliance and University of Kansas Cancer Center , is collaborating with investigators from the Center for Cell and Gene Therapy at the Baylor College of Medicine in developing new treatments for neuroblastoma, a form of pediatric cancer. This highly innovative approach uses patient-derived T cells which are genetically modified and when re-injected in the patient, target and destroy the neuroblastoma cells. 


Reversing Kidney Failure with Growth Hormones

Bradley Warady, MD, Director of the Division of Nephrology and the principal investigator for the multi-center CKIDS study, demonstrated that the administration of growth hormone to children with chronic renal failure markedly improved both physical and social functioning (i.e., quality of life); thereby validating its role as an important treatment for this condition. Read more »

Improving Infant Lung Function

William Truog, MD, a neonatologist researcher at Children's Mercy, and collaborators from Stanford University demonstrated a beneficial effect for the late administration of pulmonary surfactant therapy to improve lung function in neonates, thus demonstrating its potential role in the treatment of bronchopulmonary dysplasia.
Read more »

Leading Discoveries in Histamine Response

Bridgette Jones, MD, and collaborators from the Division of Pediatric Pharmacology and Therapeutic Innovation were the first to describe and characterize three distinct response phenotypes to the common mediator, histamine.


Copyright © 2018 The Children’s Mercy Hospital